Suppr超能文献

在小鼠中使用人源化剂量通过药代动力学/药效学研究评估米卡芬净延长给药间隔的疗效。

Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice.

作者信息

Lepak A, Marchillo K, VanHecker J, Azie N, Andes D

机构信息

University of Wisconsin, Madison, Wisconsin, USA.

Middleton VA Hospital, Madison, Wisconsin, USA.

出版信息

Antimicrob Agents Chemother. 2015 Nov 9;60(1):674-7. doi: 10.1128/AAC.02124-15. Print 2016 Jan.

Abstract

The pharmacokinetic/pharmacodynamic (PK/PD) characteristics of the echinocandins favor infrequent administration of large doses. The in vivo investigation reported here tested the utility of a range of humanized dose levels of micafungin using a variety of prolonged dosing intervals for the prevention and therapy of established disseminated candidiasis. Humanized doses of 600 mg administered every 6 days prevented fungal growth in prophylaxis. Humanized doses of 300 to 1,000 mg administered every 6 days demonstrated efficacy for established infections.

摘要

棘白菌素类药物的药代动力学/药效学(PK/PD)特性有利于大剂量的不频繁给药。本文报道的体内研究使用多种延长的给药间隔,测试了一系列人源化剂量的米卡芬净对已确诊的播散性念珠菌病的预防和治疗效果。每6天给予600mg的人源化剂量可预防真菌感染。每6天给予300至1000mg的人源化剂量对已确诊的感染显示出疗效。

相似文献

1
Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice.
Antimicrob Agents Chemother. 2015 Nov 9;60(1):674-7. doi: 10.1128/AAC.02124-15. Print 2016 Jan.
2
Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.
Antimicrob Agents Chemother. 2013 Nov;57(11):5714-6. doi: 10.1128/AAC.01057-13. Epub 2013 Aug 19.
3
Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
J Antimicrob Chemother. 2009 Oct;64(4):840-4. doi: 10.1093/jac/dkp298. Epub 2009 Aug 21.
6
In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
Antimicrob Agents Chemother. 2008 Oct;52(10):3497-503. doi: 10.1128/AAC.00478-08. Epub 2008 Jul 14.
8
The echinocandins: three useful choices or three too many?
Int J Antimicrob Agents. 2010 Jan;35(1):13-8. doi: 10.1016/j.ijantimicag.2009.09.011. Epub 2009 Nov 25.
9
Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00791-17. Print 2017 Aug.
10
Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!
Clin Infect Dis. 2015 Dec 1;61 Suppl 6:S635-42. doi: 10.1093/cid/civ715.

引用本文的文献

本文引用的文献

1
Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease.
J Antimicrob Chemother. 2015 May;70(5):1527-30. doi: 10.1093/jac/dku544. Epub 2015 Jan 5.
2
3
Safety of high-dose micafungin for patients with hematological diseases.
Leuk Lymphoma. 2014 Nov;55(11):2572-6. doi: 10.3109/10428194.2014.885514. Epub 2014 Mar 7.
4
Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.
Antimicrob Agents Chemother. 2013 Nov;57(11):5714-6. doi: 10.1128/AAC.01057-13. Epub 2013 Aug 19.
5
Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients.
Clin Microbiol Infect. 2011 Dec;17(12):1868-74. doi: 10.1111/j.1469-0691.2011.03483.x. Epub 2011 Sep 6.
7
Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.
Expert Opin Drug Saf. 2011 Mar;10(2):171-83. doi: 10.1517/14740338.2011.557062. Epub 2011 Feb 10.
10
In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
Antimicrob Agents Chemother. 2008 Oct;52(10):3497-503. doi: 10.1128/AAC.00478-08. Epub 2008 Jul 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验